^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Colorectal Cancer
    Drug:Piqray (alpelisib) (PIK3CA inhibitor) +
    Kisqali (ribociclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASCO-GI 2023
    Title:

    Synergistic effects of alpelisib (PI3K inhibitor) and ribociclib (CDK4/6 inhibitor) combination in preclinical colorectal cancer models.

    Published date:
    01/17/2023
    Excerpt:
    We explored the in vitro efficacy of drug combinations Ribociclib (R) and Alpelisib (A) in four CRC cell lines with different mutational status; CACO2 (PIK3CA/KRAS wild-type), LS1034 (KRAS mutated), SNUC4 (PIK3CA mutated) and DLD1 (PIK3CA/KRAS mutated)....Drug combination analysis showed that the combination of R and A has a synergistic anti-proliferative effect in all CRC cell lines tested. The combination of R and A is highly synergistic in LS1034 cells which harbour a KRAS mutation (CI = 0.16).
    DOI:
    10.1200/JCO.2023.41.3_suppl.167
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ESMO-TAT 2022
    Title:

    33P - Synergistic effects of Alpelisib (PI3K inhibitor) and Ribociclib (CDK 4/6 inhibitor) in preclinical colorectal cancer (CRC) models

    Published date:
    03/03/2022
    Excerpt:
    We explored the in vitro efficacy of drug combinations (Ribociclib and Alpelisib (R+A)) in four CRC cell lines with different mutational statuses; CACO-2 (PIK3CA/KRAS wildtype), LS-1034 (KRAS mutated), SNU-C4 (PIK3CA mutated), and DLD-1 (PIK3CA/KRAS mutated)....The combination of R+A is highly synergistic in LS1034 cells which harbor a KRAS mutation (CI=0.16).
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ESMO-GI 2021
    Title:

    P-287 Preclinical evaluation of alpelisib (PI3K inhibitor) and its synergistic effect in combination with ribociclib (CDK 4/6 inhibitor) in colorectal cancer

    Published date:
    07/04/2021
    Excerpt:
    ...explored the in vitro efficacy of drug combinations (ribociclib and alpelisib (R+A)) in four CRC cell lines with different mutational status; CACO-2 (PIK3CA/KRAS wildtype), LS-1034 (KRAS mutated), SNU-C4 (PIK3CA mutated), and DLD-1 (PIK3CA/KRAS mutated) cells....Drug combination analysis showed that combination of R+A has a synergistic anti-proliferative effect in all CRC cell lines tested.
    DOI:
    10.1016/j.annonc.2021.05.341